Compare ENSG & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENSG | RGC |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.8B |
| IPO Year | 2007 | 2021 |
| Metric | ENSG | RGC |
|---|---|---|
| Price | $178.97 | $22.07 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $196.40 | N/A |
| AVG Volume (30 Days) | ★ 356.5K | 238.7K |
| Earning Date | 02-04-2026 | 10-24-2025 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | ★ 35.03 | N/A |
| EPS | ★ 5.59 | N/A |
| Revenue | ★ $4,829,467,000.00 | N/A |
| Revenue This Year | $21.00 | N/A |
| Revenue Next Year | $12.30 | N/A |
| P/E Ratio | $32.45 | ★ N/A |
| Revenue Growth | ★ 17.55 | N/A |
| 52 Week Low | $118.73 | $0.09 |
| 52 Week High | $194.00 | $83.60 |
| Indicator | ENSG | RGC |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 77.80 |
| Support Level | $172.95 | $16.30 |
| Resistance Level | $180.00 | $18.10 |
| Average True Range (ATR) | 3.85 | 1.92 |
| MACD | 0.27 | 0.68 |
| Stochastic Oscillator | 64.05 | 78.07 |
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.